Im Cannabis Corp ( (IMCC) ) has released its Q3 earnings. Here is a breakdown of the information Im Cannabis Corp presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
IM Cannabis Corp. is an international medical cannabis company that provides premium cannabis products to medical patients in Israel and Germany, leveraging a transnational ecosystem powered by a data-driven approach.
In its third-quarter 2025 earnings report, IM Cannabis Corp. revealed consistent revenue figures compared to the previous year, alongside a notable decrease in gross profit and an increase in net loss, primarily due to a one-time goodwill and intangible asset impairment.
The company reported a stable revenue of $13.9 million for Q3 2025, mirroring the same period in 2024. However, gross profit decreased by 13% to $2.7 million, and the gross margin fell to 20%. Operating expenses surged by 68% due to the impairment, leading to a net loss of $3.9 million, a significant increase from the $1.1 million net loss in Q3 2024. Additionally, the Non-IFRS Adjusted EBITDA loss widened to $0.6 million from $0.2 million the previous year.
The management of IM Cannabis Corp. has acknowledged 2025 as a transition year, with potential regulatory changes in Germany posing challenges. The company is exploring new business activities to enhance growth and create long-term value. Despite the current financial setbacks, IM Cannabis remains committed to navigating the evolving market landscape.
Looking forward, IM Cannabis Corp. aims to adapt to regulatory changes and explore strategic opportunities to bolster its position in the global medical cannabis market, with a focus on maintaining compliance and responsible growth.